HRT Financial’s Definium Therapeutics DFTX Stock Holding History

HRT Financial’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-89,141	Closed	-$1.68M	–	4918
2026 Q1	$1.68M	Buy	89,141 +62,859	+239%	+$1.07M	﹤0.01%	1729
2025 Q4	$351K	Sell	26,282 -31,283	-54%	-$387K	﹤0.01%	2298
2025 Q3	$678K	Buy	+57,565	New	+$537K	﹤0.01%	1716
2025 Q2	–	Sell	-16,703	Closed	-$97K	–	3211
2025 Q1	$97K	Buy	+16,703	New	+$120K	﹤0.01%	2152
2024 Q2	–	Sell	-207,253	Closed	-$1.95M	–	2753
2024 Q1	$1.95M	Buy	+207,253	New	+$1.18M	0.01%	577
2022 Q3	–	Sell	-11,589	Closed	-$111K	–	3243
2022 Q2	$111K	Buy	11,589 +10,782	+1,336%	+$136K	﹤0.01%	2412
2022 Q1	$13K	Sell	807 -376	-32%	-$6.52K	﹤0.01%	2878
2021 Q4	$24K	Buy	+1,183	New	+$37.8K	﹤0.01%	2926

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HRT Financial's DFTX Position: Q2 2026 in Review

HRT Financial sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 89,141 shares — an estimated $1.68M sold.

HRT Financial first reported a position in DFTX in Q4 2021 and held it in 8 quarters. The position peaked at $1.95M in Q1 2024. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

HRT Financial reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 89,141 Definium Therapeutics shares in Q2 2026, an estimated $1.68M.
HRT Financial first reported a position in Definium Therapeutics in Q4 2021 and held it in 8 quarters.
HRT Financial's Definium Therapeutics position peaked at $1.95M in Q1 2024.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.